Three different replies, three different next steps
International hospital departments handle enquiries in different ways, and the wording of a first reply is often administrative rather than clinical. Reading it correctly prevents two common mistakes: treating a receipt confirmation as a green light, or treating a records request as a rejection.
A receipt confirmation means your message reached a person or a queue. Nothing has been assessed. The useful action is to ask when a clinical review will begin and who will conduct it, not to send the same file again.
A records request is the most actionable reply. It means someone looked at what you sent and identified a gap. The gap is usually specific: a pathology report without the biomarker section, a scan report without the images, or a treatment summary without dates and drug names. Reply with exactly what was asked, labelled clearly, rather than a larger archive.
A reply stating that assessment has started is the strongest of the three, but it still is not a treatment offer. Ask what the assessment covers, what the expected output is, and whether the reviewing clinician needs anything else from you before forming a view.
Why the reply must name your drug and biomarker question
Targeted cancer treatment acts on particular molecular features of a tumour. Biomarker findings can help clinicians assess potential treatment options. That means a useful reply cannot be generic. It has to connect your specific biomarker result to the specific drug or drug class you are asking about.
If your enquiry asked about a named medicine and the reply does not mention it, the reply is incomplete for your purpose. Write back with one short paragraph: the drug name, the biomarker result and test method, the date of the test, and the question you want answered. Ask directly whether the centre can assess this combination and what records it still needs.
Do not assume that a biomarker result automatically corresponds to an available option. Whether a finding is actionable depends on the tumour type, the test used, prior treatments and the treating clinician's judgement. The hospital decides suitability; a preliminary reply does not.
If you have already received targeted therapy elsewhere, say so plainly, including the drug, the start and stop dates, the reason for stopping, and the most recent response assessment. A reply that ignores your treatment history cannot meaningfully address continuation or change.
The records that turn a vague reply into a clinical question
Most delays in international enquiries come from documents that are present but unusable. A pathology report in a language the reviewer cannot read, a scan report without the image files, or a discharge summary without dates forces the reviewer to ask again.
Send the pathology report in full, including the biomarker and molecular sections, with the test method and the date. Send imaging as both the written report and the actual files where the hospital requests them. Send a treatment timeline: each drug, dose changes, start and stop dates, and the reason for each change. Send the most recent assessment of how the disease is responding.
Ask the hospital which language it accepts and whether it needs certified translation. Do not commission translation before you know, because requirements differ between centres and departments.
Keep a single index page listing every document with its date and language. This is not a clinical document, but it shortens the back-and-forth considerably and makes it obvious when something is missing.
Continuation, monitoring and the questions a reply often leaves open
If you are already on a targeted medicine, the practical question is not only whether the centre can assess your case, but how ongoing treatment and monitoring would continue. A reply that says assessment is possible has not answered that.
Ask what the centre would need in order to consider continuing your current treatment, and what monitoring it would expect during and after any change. Ask who would be responsible for follow-up, and how results would be communicated to you and to your treating team at home.
Ask whether the medicine you are asking about is something the hospital can assess and, separately, whether it can be provided. These are different questions. Assessment is a clinical judgement; provision depends on the hospital, the pharmacy and the applicable rules.
If your question involves bringing medicine into China, that is a customs and regulatory matter, not a clinical one. Ask the relevant authorities and the hospital's own international office, and do not rely on a general answer from anyone else.
How to reply so the next message is more useful
A short, structured reply works better than a long one. State what you understood from their message, supply what was requested, and ask one clear question. If the reply was ambiguous, say so and ask them to confirm which stage you are at.
Useful wording: "Thank you. I understand my records were received. Could you confirm whether a clinical assessment has started, and whether the reviewing team needs the pathology biomarker section or the imaging files before it can proceed? My specific question is whether the centre can assess [drug] in the context of [biomarker result]."
Avoid sending the same documents repeatedly, and avoid asking several unrelated clinical questions in one message. Each additional question can move your file to a different reviewer and restart the process.
Set a reasonable expectation for yourself. A preliminary reply is correspondence, not a decision. If you need care urgently, do not wait on an overseas reply; seek assessment locally.
Where ChinaSpecialistCare fits, and your next step
Before you write back, decide what you actually need from the hospital. Three outcomes are possible, and they are not the same. The first is a clinical assessment: the centre reviews your biomarker result, your treatment history and your imaging, and tells you whether it can assess the drug or drug class you asked about. The second is a statement about provision: whether the medicine itself could be supplied through that hospital, which depends on the hospital, its pharmacy and the applicable rules rather than on the clinical review alone. The third is a plan for continuation and monitoring if you are already on treatment. A reply that answers one of these has not answered the others, and mixing them into a single question is a frequent reason a second reply is still vague.
If the reply you received did not name your drug or your biomarker, treat that as the gap to close first. Write one short message that restates the drug, the biomarker result and the test method, the date of the test, and the specific question you want answered. Ask whether the centre can assess that combination and what records it still needs before it can. Keep the message to that single clinical question; a second, unrelated question can move your file to a different reviewer.
If you are already on a targeted medicine, add the practical questions that a preliminary reply leaves open. Ask what the centre would need in order to consider continuing your current treatment, what monitoring it would expect during and after any change, and who would be responsible for follow-up. Ask how results would be communicated to you and to your treating team at home, because a change made abroad has to be visible to the clinician who sees you next.
Set your own timeline for the exchange. A preliminary reply is correspondence, not a decision, and waiting on an overseas answer is not a reason to delay assessment or treatment where you are. If your situation is changing quickly, have that assessed locally while the enquiry continues.
ChinaSpecialistCare provides information and non-clinical coordination. We can help you organise records, clarify what a hospital has asked for, and request a specialist appointment. We do not diagnose, prescribe, decide suitability or promise that a hospital will accept a case or provide a particular medicine. An initial enquiry is free and needs only a brief summary, not a complete medical archive, and you do not need to buy a proxy consultation to ask a question.
If you want to understand how targeted therapy assessment is approached in China before you write back to the hospital, review the related reference page below.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.